The “Wagshurst study”: p.Val40Ile transthyretin gene variant causes late-onset cardiomyopathy

References

• Ando Y, Nakamura M, Araki S. Transthyretin-related familial amyloidotic polyneuropathy. Arch Neurol 2005;62:1057–62
   PubMed Web of Science ®Google Scholar
• Dubrey SW, Hawkins PN, Falk RH. Amyloid diseases of the heart: assessment, diagnosis, and referralAmyloid diseases of the heart: assessment, diagnosis, and referral. Heart 2011;97:75–84
   PubMed Web of Science ®Google Scholar
• Benson MD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve 2007;36:411–23
   PubMed Web of Science ®Google Scholar
• Rapezzi C, Quarta CC, Obici L, Perfetto F, Longhi S, Salvi F, Biagini E, et al. Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Heart J 2013;34:520–8
   PubMed Web of Science ®Google Scholar
• Shah PL, Gillmore JD, Copley SJ, Collins JV, Wells AU, du Bois RM, Hawkins PN, et al. The importance of complete screening for amyloid fibril type and systemic disease in patients with amyloidosis in the respiratory tract. Sarcoidosis Vasc Diffuse Lung Dis 2002;19:134–42
   PubMed Web of Science ®Google Scholar
• Roden AC, Aubry MC, Zhang K, Brady JO, Levin D, Dogan A, Yi ES. Nodular senile pulmonary amyloidosis: a unique case confirmed by immunohistochemistry, mass spectrometry, and genetic study. Hum Pathol 2010;41:1040–5
   PubMedGoogle Scholar
• Westermark P, Bergström J, Solomon A, Murphy C, Sletten K. Transthyretin-derived senile systemic amyloidosis: clinicopathologic and structural considerations. Amyloid 2003;10:48–54
   PubMed Web of Science ®Google Scholar
• Sack FU, Kristen A, Goldschmidt H, Schnabel PA, Dengler T, Koch A, Karck M. Treatment options for severe cardiac amyloidosis: heart transplantation combined with chemotherapy and stem cell transplantation for patients with AL-amyloidosis and heart and liver transplantation for patients with ATTR-amyloidosis. Eur J Cardiothorac Surg 2008;33:257–62
   PubMed Web of Science ®Google Scholar
• Mohty D, Damy T, Cosnay P, Echahidi N, Casset-Senon D, Virot P, Jaccard A. Cardiac amyloidosis: updates in diagnosis and management. Arch Cardiovasc Dis 2013;106:528–40
   PubMed Web of Science ®Google Scholar
• Suhr OB, Svendsen IH, Andersson R, Danielsson A, Holmgren G, Ranløv PJ. Hereditary transthyretin amyloidosis from a Scandinavian perspective. J Intern Med 2003;254:225–35
   PubMed Web of Science ®Google Scholar
• Bittencourt PL, Couto CA, Clemente C, Farias AQ, Palácios SA, Mies S, Goldberg AC, et al. Phenotypic expression of familial amyloid polyneuropathy in Brazil. Eur J Neurol 2005;12:289–93
   PubMed Web of Science ®Google Scholar
• Conceicao I, De Carvalho M. Clinical variability in type I familial amyloid polyneuropathy (Val30Met): comparison between late- and early-onset cases in Portugal. Muscle Nerve 2007;35:116–18
   PubMed Web of Science ®Google Scholar
• Rapezzi C, Quarta CC, Riva L, Longhi S, Gallelli I, Lorenzini M, Ciliberti P, et al. Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol 2010;7:398–408
   PubMed Web of Science ®Google Scholar
• Rapezzi C, Longhi S, Milandri A, Lorenzini M, Gagliardi C, Gallelli I, Leone O, et al. Cardiac involvement in hereditary-transthyretin related amyloidosis. Amyloid 2012;19:16–21
   PubMed Web of Science ®Google Scholar
• Ihse E, Ybo A, Suhr O, Lindqvist P, Backman C, Westermark P. Amyloid fibril composition is related to the phenotype of hereditary transthyretin V30M amyloidosis. J Pathol 2008;216:253–61
   PubMed Web of Science ®Google Scholar
• Dwulet FE, Benson MD. Primary structure of an amyloid prealbumin and its plasma precursor in a heredofamilial polyneuropathy of Swedish origin. Proc Natl Acad Sci USA 1984;81:694–8
   PubMed Web of Science ®Google Scholar
• Ikeda S, Nakazato M, Ando Y, Sobue G. Familial transthyretin-type amyloid polyneuropathy in Japan: clinical and genetic heterogeneity. Neurology 2002;58:1001–7
   PubMed Web of Science ®Google Scholar
• Connors LH, Prokaeva T, Lim A, Théberge R, Falk RH, Doros G, Berg A, et al. Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis. Am Heart J 2009;158:607–14
   PubMed Web of Science ®Google Scholar
• Jacobson DR, Pastore RD, Yaghoubian R, Kane I, Gallo G, Buck FS, Buxbaum JN. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med 1997;336:466–73
   PubMed Web of Science ®Google Scholar
• Jacobson DR, Gorevic PD, Buxbaum JN. A homozygous transthyretin variant associated with senile systemic amyloidosis: evidence for a late-onset disease of genetic etiology. Am J Hum Genet 1990;47:127–36
   PubMed Web of Science ®Google Scholar
• Sattianayagam PT, Hahn AF, Whelan CJ, Gibbs SD, Pinney JH, Stangou AJ, Rowczenio D, et al. Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant. Eur Heart J 2012;33:1120–7
   PubMed Web of Science ®Google Scholar
• Jacobson DR, Pan T, Kyle RA, Buxbaum JN. Transthyretin ILE20, a new variant associated with late-onset cardiac amyloidosis. Hum Mutat 1997;9:83–5
   PubMed Web of Science ®Google Scholar
• Jenne DE, Denzel K, Blätzinger P, Winter P, Obermaier B, Linke RP, Altland K. A new isoleucine substitution of Val-20 in transthyretin tetramers selectively impairs dimer-dimer contacts and causes systemic amyloidosis. Proc Natl Acad Sci USA 1996;93:6302–7
   PubMed Web of Science ®Google Scholar
• Altland K, Benson MD, Costello CE, Ferlini A, Hazenberg BP, Hund E, Kristen AV, et al. Genetic microheterogeneity of human transthyretin detected by IEF. Electrophoresis 2007;28:2053–64
   PubMed Web of Science ®Google Scholar
• Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, et al. Recommendation for chamber quantification: a report from the American society of echocardiography’s guidelines and standards committee and left chamber quantification group, in conjunction with the European association of echocardiography. J Am Soc Echocardiogr 2005;18:1440–63
   PubMed Web of Science ®Google Scholar
• Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, Waggoner AD, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 2009;22:107–33
   PubMed Web of Science ®Google Scholar
• Puille M, Altland K, Linke RP, Steen-Muller MK, Kiett R, Steiner D, Bauer R. 99mTc DPD scintigraphy in transthyretin-related familial amyloidotic polyneuropathy. Eur J Nucl Med Mol Imaging 2002;29:376–9
   PubMed Web of Science ®Google Scholar
• Lehrke S, Steen H, Kristen AV, Merten C, Lossnitzer D, Dengler TJ, Katus HA, et al. Serum levels of NT-proBNP as surrogate for cardiac amyloid burden: new evidence from gadolinium-enhanced cardiac magnetic resonance imaging in patients with amyloidosis. Amyloid 2009;16:187–95
   PubMed Web of Science ®Google Scholar
• Chuang ML, Gona P, Salton CJ, Yeon SB, Kissinger KV, Blease SJ, Levy D, et al. Usefulness of the left ventricular myocardial contraction fraction in healthy men and women to predict cardiovascular morbidity and mortality. Am J Cardiol 2012;109:1454–8
   PubMed Web of Science ®Google Scholar
• Okamoto S, Hörnsten R, Obayashi K, Wijayatunga P, Suhr OB. Continuous development of arrhythmia is observed in Swedish transplant patients with familial amyloidotic polyneuropathy (amyloidogenic transthyretin Val30Met variant). Liver Transpl 2011;17:122–8
   PubMed Web of Science ®Google Scholar
• Reddi HV, Jenkins S, Theis J, Thomas BC, Connors LH, Van Rhee F, Highsmith WE Jr. Homozygosity for the V122I mutation in transthyretin is associated with earlier onset of cardiac amyloidosis in the African American population in the seventh decade of life. J Mol Diagn 2014;16:68–74
   PubMed Web of Science ®Google Scholar
• Brenner DA, Jain M, Pimentel DR, Wang B, Connors LH, Skinner M, Apstein CS, et al. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res 2004;30:1008–10
   Google Scholar
• Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, Greipp PR, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 2004;22:3751–7
   PubMed Web of Science ®Google Scholar
• Palladini G, Campana C, Klersy C, Balduini A, Vadacca G, Perfetti V, Perlini S, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003;107:2440–5
   PubMed Web of Science ®Google Scholar
• Kristen AV, Sack FU, Dösch A, Schnabel PA, Katus HA, Dengler TJ. The seven year itch? Promising long-term survival after heart transplant in a patient with transthyretin amyloidosis. Aktuel Kardiol 2012;1:286–9
   Google Scholar
• Koike H, Kiuchi T, Iijima M, Ueda M, Ando Y, Morozumi S, Tomita M, et al. Systemic but asymptomatic transthyretin amyloidosis 8 years after domino liver transplantation. J Neurol Neurosurg Psychiatr 2011;82:1287–90
   PubMed Web of Science ®Google Scholar
• Ueda M, Ando Y, Haraoka K, Katsuragi S, Terasaki Y, Sugimoto M, Sun X, et al. Aging and transthyretin-related amyloidosis: pathologic examinations in pulmonary amyloidosis. Amyloid 2006;13:24–30
   PubMed Web of Science ®Google Scholar
• Shah PL, Gillmore JD, Copley SJ, Collins JV, Wells AU, du Bois RM, Hawkins PN, et al. The importance of complete screening for amyloid fibril type and systemic disease in patients with amyloidosis in the respiratory tract. Sarcoidosis Vasc Diffuse Lung Dis 2002;19:134–42
   PubMed Web of Science ®Google Scholar